ENDO OPERATIONS
SpecialtyENDO OPERATIONS is a specialty pharmaceutical company focused on Neurology, Oncology, Respiratory. Key products include AVEED.
ENDO OPERATIONS at a Glance
- Fast trial execution (14 months median completion)
ENDO OPERATIONS's Key Drugs
ENDO OPERATIONS's core commercial portfolio centers on AVEED, spanning Neurology and Oncology — its most strategically important drugs approved in the last 15 years.
ENDO OPERATIONS's Recent FDA Approvals
New NDA/BLA approvals for ENDO OPERATIONS over the last two years — novel drugs only, excluding generics and label supplements.
ENDO OPERATIONS's Therapeutic Areas
ENDO OPERATIONS's approved drugs and pipeline span 3 therapeutic areas, led by Neurology and Oncology, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ENDO OPERATIONS's Top Competitors
ENDO OPERATIONS's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Pfizer, and AZURITY. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ENDO OPERATIONS Pipeline Snapshot
Active clinical trials for ENDO OPERATIONS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 15/23 completed
- • Speed: 14 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1950-04-12
- Latest
- 2026-06-18
- Applications
- 20
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges